Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib

SIMPLE SUMMARY: Systemic therapy in advanced hepatocellular-carcinomas (HCC) has limited benefits, but some patients show partial responses (PR) and a few even a complete response (CR). Understanding the biological mechanisms could help clinicians in decision-making. Aim of this study was to develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Colombatto, Piero, Demirtas, Coskun Ozer, Ricco, Gabriele, Civitano, Luigi, Boraschi, Piero, Scalise, Paola, Cavallone, Daniela, Oliveri, Filippo, Romagnoli, Veronica, Bleve, Patrizia, Coco, Barbara, Salvati, Antonio, Urbani, Lucio, Bonino, Ferruccio, Brunetto, Maurizia Rossana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123288/
https://www.ncbi.nlm.nih.gov/pubmed/33922938
http://dx.doi.org/10.3390/cancers13092064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123288/
https://www.ncbi.nlm.nih.gov/pubmed/33922938
http://dx.doi.org/10.3390/cancers13092064

Ejemplares similares